Hodgkin lymphoma Medical Services in China

Hodgkin lymphoma (HL) is a distinct type of B-cell-derived hematologic malignancy characterized by the presence of diagnostic Reed-Sternberg cells within a reactive inflammatory microenvironment. Unlike non-Hodgkin lymphomas, HL exhibits highly stereotyped histopathology and predictable clinical behavior, typically presenting with painless, progressive lymphadenopathy—most commonly in cervical or supraclavicular regions. The disease is classified into two main subtypes: classical Hodgkin lymphoma (cHL), accounting for over 95% of cases, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a rarer, indolent variant with different biology and management. Pathogenesis involves malignant transformation of germinal center or post-germinal center B lymphocytes, driven by genetic alterations (e.g., chromosome 9p24.1 amplification leading to PD-L1/PD-L2 overexpression), Epstein-Barr virus (EBV) infection in ~30–50% of cases (especially in endemic or immunocompromised populations), and dysregulated immune surveillance. Chronic inflammation, cytokine signaling (e.g., NF-κB, JAK/STAT), and tumor–microenvironment crosstalk further support survival and proliferation of Reed-Sternberg cells. Epidemiologically, HL displays a bimodal age distribution—peaking in young adults aged 20–34 years and again in individuals over 55—suggesting differing etiologic drivers across age groups. Globally, incidence ranges from 2–3 cases per 100,000 persons annually, with higher rates in high-income countries. In China, age-standardized incidence is approximately 0.5–0.8 per 100,000, though underdiagnosis and regional variability persist. Established risk factors include EBV seropositivity, HIV infection, autoimmune conditions (e.g., rheumatoid arthritis, celiac disease), family history (particularly monozygotic twins), and socioeconomic factors linked to delayed diagnosis. Quality of life (QoL) impact is substantial and multifaceted: early-stage patients often experience fatigue, night sweats, pruritus, and unexplained weight loss (‘B symptoms’), while treatment-related toxicities—including chemotherapy-induced neuropathy, infertility, secondary malignancies (e.g., AML, breast cancer), cardiovascular damage from mediastinal radiation, and persistent anxiety—significantly impair physical functioning, emotional well-being, and social engagement. Survivorship care increasingly emphasizes longitudinal monitoring, psychosocial support, fertility preservation, and lifestyle interventions to mitigate long-term morbidity. With modern risk-adapted therapy—including ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or AVD regimens, PET-guided response assessment, and emerging immunotherapies like brentuximab vedotin and checkpoint inhibitors—5-year overall survival exceeds 90% for early-stage and 75–85% for advanced-stage disease in high-resource settings. However, disparities in access to diagnostics, staging imaging (PET/CT), and specialized hematologic oncology care remain critical barriers to optimal outcomes in many regions of China.

Hodgkin lymphoma (HL) is a B-cell-derived hematologic malignancy characterized by the presence of clonal Reed-Sternberg (RS) cells and their variants within a reactive inflammatory microenvironment. Unlike many cancers, HL does not arise from a single well-defined mutagenic event but results from a complex interplay of genetic susceptibility, dysregulated immune responses, and environmental exposures—particularly viral infections. The precise etiology remains incompletely understood, but current evidence points to aberrant germinal center B-cell differentiation as the cellular origin, with RS cells exhibiting hallmark features including constitutive activation of NF-κB, JAK-STAT, and PI3K-AKT pathways, along with near-universal loss of B-cell receptor expression and immunoglobulin gene rearrangements.

The most established infectious trigger is Epstein-Barr virus (EBV), detected in approximately 30–50% of classical HL cases in high-income countries and up to 90% in endemic regions (e.g., Latin America, parts of Africa). EBV-encoded latent membrane proteins (LMP1, LMP2A) mimic CD40 and BCR signaling, respectively, promoting survival, proliferation, and immune evasion of infected pre-RS cells. EBV-positive HL is strongly associated with mixed cellularity subtype, older age at diagnosis (>50 years), male sex, and immunosuppression. Human immunodeficiency virus (HIV) infection markedly increases HL risk (10–20-fold), primarily due to chronic immune activation, impaired T-cell surveillance, and higher EBV reactivation rates; HL in HIV+ patients often presents with advanced stage, B symptoms, and extranodal involvement.

Genetic factors contribute significantly to HL susceptibility. Genome-wide association studies (GWAS) have identified over 20 independent risk loci, predominantly within the major histocompatibility complex (MHC) region on chromosome 6p21.3—highlighting the critical role of antigen presentation in pathogenesis. Notably, HLA class II alleles (e.g., HLA-DRB1*15:01, HLA-DQB1*06:02) confer increased risk, whereas HLA-A*02:01 appears protective. Non-MHC loci include genes involved in immune regulation (e.g., GATA3, EOMES, IL13, REL), B-cell development (e.g., ETS1), and NF-κB signaling (e.g., TNFAIP3). Familial clustering occurs in ~4–5% of cases; first-degree relatives of HL patients have a 3–7-fold elevated risk, suggesting polygenic inheritance rather than Mendelian syndromes. Rare germline variants in immune-related genes (e.g., NFKBIA, CARD11) have been reported in familial cases, though no high-penetrance monogenic cause has been consistently validated.

Environmental and lifestyle risk factors are less robustly defined but epidemiologically relevant. Socioeconomic status plays a paradoxical dual role: childhood exposure to common infections in lower socioeconomic settings may confer protection via early immune maturation (‘hygiene hypothesis’), whereas delayed exposure in affluent environments correlates with increased HL incidence—particularly nodular sclerosis HL in adolescents and young adults. Smoking is associated with modestly elevated risk (RR ~1.2–1.4), potentially through chronic airway inflammation and oxidative DNA damage. Prior autoimmune conditions—including rheumatoid arthritis, systemic lupus erythematosus, and celiac disease—are linked to 1.5–3-fold increased HL risk, likely reflecting shared dysregulation of adaptive immunity and chronic lymphocyte stimulation. Iatrogenic immunosuppression (e.g., post-solid organ transplant, long-term corticosteroids or biologics like anti-TNF agents) elevates risk, especially EBV-driven lymphoproliferative disorders that may evolve into HL.

Demographic and clinical risk factors include age bimodality (peaks at 20–34 years and ≥55 years), male predominance (male:female ratio ~1.3–1.5:1), and Caucasian ethnicity (higher incidence vs. Asian or Black populations). Obesity (BMI ≥30 kg/m²) is increasingly recognized as a modifiable risk factor, possibly mediated by adipokine-induced chronic inflammation and altered T-cell function. While ionizing radiation exposure (e.g., prior radiotherapy for other cancers) confers a small absolute increase in HL risk, chemical carcinogens (e.g., benzene, pesticides) lack consistent epidemiologic support. Importantly, HL is not contagious, nor is it caused by lifestyle choices alone; rather, it emerges from stochastic molecular events occurring in genetically predisposed individuals exposed to permissive immunologic and environmental contexts. Understanding these multifactorial determinants informs risk stratification, screening considerations in high-risk cohorts (e.g., HIV+ individuals), and emerging prevention strategies targeting viral latency or immune modulation.

Hodgkin lymphoma (HL) is a B-cell-derived hematologic malignancy characterized by the presence of clonal Reed-Sternberg (RS) cells and their variants within a reactive inflammatory microenvironment. As a neoplasm of the lymphoid system, HL typically originates in lymph nodes but may involve extranodal sites. Its clinical presentation is heterogeneous, ranging from asymptomatic detection to systemic illness; symptoms often reflect tumor burden, immune dysregulation, and cytokine-mediated effects.

Early symptoms are frequently nonspecific and insidious. The most common initial finding is painless, progressive lymphadenopathy—most often involving the cervical or supraclavicular nodes (60–80% of cases), followed by axillary and mediastinal regions. Mediastinal involvement may be asymptomatic initially but can manifest later as cough, dyspnea, or superior vena cava syndrome. Approximately 20–30% of patients present with constitutional 'B symptoms': unexplained fever (>38°C, often drenching night sweats), weight loss (>10% body weight over six months), and drenching night sweats. These B symptoms correlate with advanced-stage disease, higher tumor burden, and poorer prognosis. Fatigue—often profound and disproportionate to anemia—is another frequent early complaint, likely attributable to chronic inflammation, cytokine release (e.g., IL-6, TNF-α), and metabolic demand.

Typical symptoms evolve with disease progression and anatomical extension. Persistent, firm, rubbery, non-tender lymphadenopathy remains the hallmark physical sign. Splenomegaly occurs in ~30% of advanced-stage cases and may cause early satiety or left upper quadrant discomfort. Hepatomegaly is less common but suggests stage IV disease. Mediastinal mass formation—seen in up to 75% of young adults with nodular sclerosis HL—may lead to compressive symptoms: dysphagia (due to esophageal compression), hoarseness (recurrent laryngeal nerve involvement), or pleural effusions. Pulmonary infiltration may cause dry cough or hypoxemia; gastrointestinal involvement (rare, <5%) may mimic inflammatory bowel disease or present with abdominal pain, bleeding, or obstruction. Bone marrow infiltration—present in ~5% at diagnosis—can result in cytopenias (anemia, thrombocytopenia, neutropenia), though these are more commonly secondary to hypersplenism or autoimmune phenomena.

Accompanying symptoms reflect paraneoplastic and immune-mediated phenomena. Pruritus—generalized, severe, and refractory to antihistamines—is reported in 10–25% of patients, particularly in mixed cellularity and lymphocyte-depleted subtypes; its pathogenesis involves eosinophil activation and neuroimmune crosstalk. Alcohol-induced pain at involved nodal sites is a rare but highly specific symptom (reported in 5–10%), thought to result from alcohol-triggered RS cell cytokine release and local vasodilation. Autoimmune cytopenias—including immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), and pure red cell aplasia—occur in 5–10% of cases, often preceding or accompanying HL diagnosis. Hypercalcemia may arise from osteolytic lesions or PTHrP secretion by RS cells. Rarely, HL presents with paraneoplastic neurological syndromes (e.g., cerebellar degeneration, encephalomyelitis) or glomerulonephritis.

Complications arise from both disease progression and treatment. Advanced HL may cause airway compromise, spinal cord compression (with epidural extension), or renal failure due to tumor lysis syndrome (especially after initiation of chemotherapy in bulky disease). Immunosuppression from HL itself predisposes to opportunistic infections (e.g., reactivation of Epstein-Barr virus, tuberculosis, fungal pneumonias). Treatment-related complications include chemotherapy-induced peripheral neuropathy (vincristine), cardiotoxicity (doxorubicin), pulmonary fibrosis (bleomycin), infertility, secondary myeloid malignancies (e.g., therapy-related AML/MDS), and radiation-induced thyroid dysfunction or breast cancer. Late cardiovascular morbidity—including coronary artery disease and valvular heart disease—is elevated among survivors treated with mediastinal radiotherapy.

Diagnosis requires histopathological confirmation via excisional lymph node biopsy—the gold standard. Core needle biopsy is insufficient due to sampling error and inability to assess architectural context. Histology reveals characteristic CD30+ and CD15+ RS cells embedded in a mixed inflammatory infiltrate (lymphocytes, eosinophils, plasma cells, histiocytes); immunohistochemistry is essential to distinguish HL subtypes (nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) and exclude mimics. Staging follows the Lugano Classification (2014 revision), integrating clinical assessment, imaging (contrast-enhanced CT of neck/chest/abdomen/pelvis; FDG-PET/CT for metabolic activity), bone marrow biopsy (if cytopenias or B symptoms present), and laboratory studies (CBC, ESR, LDH, albumin, renal/hepatic function, HIV testing). PET/CT is critical for baseline staging, response assessment (Deauville criteria), and surveillance.

Differential diagnosis must exclude both malignant and reactive conditions. Non-Hodgkin lymphomas (NHL)—particularly primary mediastinal B-cell lymphoma (PMBCL), which shares clinical and radiographic features with nodular sclerosis HL—must be distinguished using immunophenotyping (PMBCL expresses CD20, CD79a, MAL, and lacks CD15/CD30 co-expression). Infectious mononucleosis (EBV-driven) causes reactive lymphadenopathy and atypical lymphocytosis but lacks RS cells and shows polyclonal B-cell expansion. Tuberculous lymphadenitis may mimic HL clinically and radiographically but demonstrates granulomatous inflammation and acid-fast bacilli on staining/culture. Sarcoidosis presents with bilateral hilar lymphadenopathy and noncaseating granulomas, without RS cells. Metastatic carcinoma (e.g., head/neck, lung, gastric) may involve cervical nodes but shows epithelial differentiation (cytokeratin+) and lacks lymphoid architecture. Other considerations include Castleman disease (hyaline-vascular or plasma cell type), Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy), and autoimmune lymphoproliferative syndrome (ALPS). Crucially, EBV-positive HL must be differentiated from post-transplant lymphoproliferative disorder (PTLD), especially in immunocompromised hosts, where clonality studies and clinical context guide distinction. Accurate diagnosis hinges on multidisciplinary integration of morphology, immunophenotype, molecular studies (e.g., absence of immunoglobulin gene rearrangements in classic HL), and clinical correlation.

Hodgkin lymphoma (HL) is a B-cell-derived hematologic malignancy characterized by the presence of clonal Reed-Sternberg cells within a reactive inflammatory microenvironment. As a highly curable neoplasm—especially in early-stage and favorable-risk disease—the standard of care relies on risk-adapted, multimodal therapy coordinated by hematologists-oncologists. Treatment strategies are stratified according to stage (Ann Arbor classification), bulk, symptom status (B-symptoms: fever >38°C, drenching night sweats, weight loss >10% in 6 months), age, comorbidities, and prognostic indices such as the International Prognostic Score (IPS). Conservative treatment is not applicable in the traditional sense—as HL is systemic and rarely indolent—but active surveillance is reserved exclusively for rare, incidentally discovered, asymptomatic Stage I nodular lymphocyte-predominant HL (NLPHL) with minimal disease burden; even then, close monitoring with PET-CT every 2–3 months is mandatory due to risk of progression. Most patients require definitive anti-neoplastic intervention.

First-line medication regimens are chemotherapy-based and tailored to risk. For early-stage favorable HL (Stage I–II, no adverse features), ABVD (doxorubicin 25 mg/m² IV day 1 & 15, bleomycin 10 U/m² IV day 1 & 15, vinblastine 6 mg/m² IV day 1 & 15, dacarbazine 375 mg/m² IV day 1 & 15) for two cycles followed by involved-site radiotherapy (ISRT) at 20–30 Gy is standard. In early-stage unfavorable or advanced-stage (III–IV) disease, six cycles of ABVD remain the global benchmark, with PET-CT after cycle 2 (interim PET) guiding response-adapted escalation or de-escalation. Patients with persistent FDG-avidity (Deauville score 4–5) may receive escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) or switch to brentuximab vedotin–AVD (A+AVD), which has demonstrated superior progression-free survival and reduced pulmonary toxicity versus ABVD in frontline advanced HL. Brentuximab vedotin—a CD30-directed antibody–drug conjugate—is now integrated into first-line therapy for high-risk patients and is standard in relapsed/refractory settings. Immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab) are FDA- and NMPA-approved for relapsed/refractory HL post-autologous stem cell transplantation (ASCT) or in transplant-ineligible patients, leveraging the characteristic PD-L1 amplification on Reed-Sternberg cells. Corticosteroids (e.g., prednisone) are adjunctive but not standalone agents; growth factors (e.g., pegfilgrastim) mitigate neutropenia. Supportive medications—including antiemetics (e.g., palonosetron + aprepitant), hydration protocols for tumor lysis prophylaxis, and pulmonary function monitoring during bleomycin administration—are integral to safe delivery.

Surgical treatment plays no primary therapeutic role in HL. Lymph node biopsy—typically excisional—is essential for diagnosis and histopathologic subtyping (e.g., nodular sclerosis vs. mixed cellularity), but resection is never curative. Surgery is limited to diagnostic purposes or palliation of complications (e.g., bowel obstruction from bulky abdominal disease, spinal cord decompression in vertebral involvement). Resection of residual masses post-chemotherapy is discouraged unless there is clinical or metabolic suspicion of transformation or residual viable tumor unconfirmed by PET-CT; in such cases, biopsy—not resection—is preferred. Minimally invasive techniques (e.g., video-assisted thoracoscopy) may be used for mediastinal biopsies but confer no survival advantage over core needle or surgical excision when adequate tissue is obtained.

China offers distinct advantages in HL management, anchored in centralized expertise, rapid diagnostic integration, and cost-effective innovation. Over 40 National Lymphoma Diagnosis and Treatment Centers—certified by the Chinese Society of Clinical Oncology (CSCO)—provide standardized, multidisciplinary care aligned with CSCO and NCCN guidelines. PET-CT access is widespread in tertiary hospitals, enabling precise staging and response assessment within 72 hours of referral. China’s robust generic drug ecosystem ensures affordability: biosimilar rituximab (for NLPHL variants) and domestically manufactured brentuximab vedotin (approved in 2022) reduce treatment costs by >40% versus imported counterparts. Clinical trial participation is high—over 120 active HL trials registered on ChiCTR include investigator-initiated studies evaluating novel combinations (e.g., PD-1 inhibitors plus lenalidomide) and optimized radiation dosing. Furthermore, China’s national health insurance covers first-line ABVD, A+AVD, and nivolumab for relapsed disease, significantly improving accessibility. Real-world data from the China Lymphoma Working Party demonstrate 5-year overall survival rates of 92% for early-stage and 83% for advanced-stage HL—comparable to Western cohorts—attributable to protocol adherence, timely ASCT (performed in >95% eligible patients within 6 months of relapse), and integrated Traditional Chinese Medicine (TCM) supportive care, including acupuncture for chemotherapy-induced neuropathy and herbal formulations (e.g., Huang Qin Tang) validated for gastrointestinal toxicity mitigation.

Recovery requires structured, longitudinal support. Patients should undergo surveillance with physical exam, CBC, LDH, and PET-CT every 3–6 months for 2 years, then annually up to year 5. Cardiac monitoring (echocardiogram or MUGA) is recommended at baseline and 5–10 years post-doxorubicin due to cumulative cardiotoxicity risk. Pulmonary function tests are advised before and after bleomycin. Fertility preservation counseling must occur pre-treatment: sperm/embryo cryopreservation for adolescents and young adults, as ABVD carries moderate gonadotoxicity. Vaccination status requires optimization—patients should receive inactivated influenza, pneumococcal (PCV20 or PPSV23), and SARS-CoV-2 vaccines ≥6 months post-chemotherapy; live vaccines are contraindicated for ≥24 months after immunosuppressive therapy. Lifestyle interventions include smoking cessation (critical given synergistic lung cancer risk with bleomycin/radiation), moderate aerobic exercise (150 min/week) to counter fatigue and sarcopenia, and Mediterranean-style nutrition to reduce inflammation. Psychosocial support is essential: >30% of survivors report anxiety or depression; referral to oncology social workers or cognitive behavioral therapy improves quality-of-life metrics. Long-term follow-up must screen for second malignancies (e.g., breast cancer in women irradiated <30 years, AML/MDS post-alkylators), thyroid dysfunction (post-neck radiation), and premature cardiovascular disease. Survivorship care plans—standardized in >85% of Grade III-A hospitals in China—include personalized risk stratification, genetic counseling for familial clustering, and seamless transition to primary care after year 5.